Prevalence and Factors Associated With Statin Use Among a Nationally Representative Sample of US Adults: National Health and Nutrition Examination Survey, 2011–2012

Clinical Cardiology

Volumn 39, Issue 9, 2016, Pages 491-496

  Adedinsewo, Demilade ^a,b   Taka, Nchang ^a,b   Agasthi, Pradyumna ^a,b   Sachdeva, Rajesh ^a,b   Rust, George ^c   Onwuanyi, Anekwe ^a,b  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b Grady Memorial Hospital   (Georgia)

^c FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical; Epidemiology; Lipidology; Pharmacology; Preventive cardiology

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; AGED; AMERICAN; ARTICLE; ASYMPTOMATIC DISEASE; ATHEROSCLEROSIS; BLACK PERSON; CARDIOVASCULAR DISEASE; CAUCASIAN; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; DYSLIPIDEMIA; FACTOR ANALYSIS; FEMALE; HEALTH INSURANCE; HEALTH SURVEY; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; RACE DIFFERENCE; REFERENCE VALUE; RISK ASSESSMENT; UNITED STATES; AFRICAN AMERICAN; AGE; BLOOD; CHI SQUARE DISTRIBUTION; COMORBIDITY; DYSLIPIDEMIAS; EPIDEMIOLOGY; ETHNOLOGY; HEALTH CARE DISPARITY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITION; ODDS RATIO; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; YOUNG ADULT;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; ATHEROSCLEROSIS; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUTRITION SURVEYS; ODDS RATIO; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RISK FACTORS; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84994246606     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22577     Document Type: Article

References (31)

1. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins [published corrections appear in Lancet. 2005;366:1358 and 2008;371:2084]. Lancet. 2005;366:1267–1278.
2. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
3. Ginsberg HN. Review: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006;91:383–392.
4. Nissen SE, Nicholls SJ, Sipahi I, et al; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565.
5. Albert MA, Danielson E, Rifai N, et al; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE), a randomized trial and cohort study. JAMA. 2001;286:64–70.
6. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 2006;6:360–374.
7. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4:341–353.
8. Lardizabal JA, Deedwania P. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease. Cardiol Clin. 2011;29:87–103.
9. Canestaro WJ, Brooks DG, Chaplin D, et al. Statin pharmacogenomics: opportunities to improve patient outcomes and healthcare costs with genetic testing. J Pers Med. 2012;2:158–174.
10. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422–1431.
11. Alagona P Jr, Ahmad TA. Cardiovascular disease risk assessment and prevention: current guidelines and limitations. Med Clin North Am. 2015;99:711–731.
12. Go AS, Mozaffarian D, Roger VL, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127:143–152.
13. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497.
14. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published corrections appear in J Am Coll Cardiol. 2014;63(25 part B):3024–3025 and 2015;66:2812]. J Am Coll Cardiol. 2014;63(25 part B):2889–2934.
15. Zipf G, Chiappa M, Porter KS, et al. National Health and Nutrition Examination Survey: plan and operations, 1999–2010. Vital Health Stat 1. 2013:1–37.
16. US Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey data. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011–2012. http://wwwn.cdc.gov/nchs/nhanes/search/nhanes11_12.aspx. Accessed May 1, 2015.
17. National Health and Nutrition Examination Survey. 2011–2012 Data Documentation, Codebook, and Frequencies. Prescription Medications (RXQ_RX_G). http://wwwn.cdc.gov/Nchs/Nhanes/2011-2012/RXQ_RX_G.htm. Accessed May 1, 2015.
18. Mann D, Reynolds K, Smith D, et al. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program guidelines. Ann Pharmacother. 2008;42:1208–1215.
19. Lazar LD, Pletcher MJ, Coxson PG, et al. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146–153.
20. Deaño RC, Pandya A, Jones EC, et al. A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines. Curr Atheroscler Rep. 2014;16:438.
21. Wei MY, Ito MK, Cohen JD, et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7:472–483.
22. Ma J, Sehgal NL, Ayanian JZ, et al. National trends in statin use by coronary heart disease risk category. PLoS Med. 2005;2:e123.
23. Phelan JC, Link BG, Diez-Roux A, et al. “Fundamental causes” of social inequalities in mortality: a test of the theory [published correction appears in J Health Soc Behav. 2005;46:v]. J Health Soc Behav. 2004;45:265–285.
24. Levine RS, Rust GS, Pisu M, et al. Increased Black-White disparities in mortality after the introduction of lifesaving innovations: a possible consequence of US federal laws. Am J Public Health. 2010;100:2176–2184.
25. Rust G, Levine RS, Fry-Johnson Y, et al. Paths to success: optimal and equitable health outcomes for all. J Health Care Poor Underserved. 2012;23(2 suppl):7–19.
26. Rust G, Zhang S, Malhotra K, et al. Paths to health equity: local area variation in progress toward eliminating breast cancer mortality disparities, 1990–2009. Cancer. 2015;121:2765–2774.
27. Levine RS, Rust G, Aliyu M, et al. United States counties with low black male mortality rates. Am J Med. 2013;126:76–80.
28. Fry-Johnson YW, Levine R, Rowley D, et al. United States black:white infant mortality disparities are not inevitable: identification of community resilience independent of socioeconomic status. Ethn Dis. 2010;20(1 suppl 1):S131–S135.
29. Zhang S, McGoy SL, Dawes D, et al. The potential for elimination of racial-ethnic disparities in HIV treatment initiation in the Medicaid population among 14 southern states. PLoS One. 2014;9:e96148.
30. Abara WE, Smith L, Zhang S, et al. The influence of race and comorbidity on the timely initiation of antiretroviral therapy among older persons living with HIV/AIDS. Am J Public Health. 2014;104:e135–e141.
31. King WD, Minor P, Ramirez Kitchen C, et al. Racial, gender and geographic disparities of antiretroviral treatment among US Medicaid enrollees in 1998. J Epidemiol Community Health. 2008;62:798–803.